| Group Var-HSA | Group Var+HSA |
---|
N | SRR (95% CI), % | GMC (95% CI), mIU/mL | N | SRR (95% CI), % | GMC (95% CI), mIU/mL |
---|
Post-dose 1 | 185 | 94.1 (89.6–97.0) | 139.9 (126.7–154.5) | 168 | 98.8 (95.8–99.9) | 146.0 (132.5–160.7) |
Post-dose 2 | 180 | 100 (98.0–100) | 931.8 (841.1–1032.3) | 173 | 100 (97.9–100) | 1102.4 (996.1–1220.2) |
- Group Var-HSA participants receiving varicella vaccine produced without HSA (human albumin serum), Group Var+HSA participants receiving varicella vaccine containing HSA, N number of participants with available results, SRR seroresponse rate, CI confidence interval, GMC geometric mean concentration, IU international units
- Note: Seroresponse was defined as post-vaccination anti-varicella-zoster virus antibody concentrations ≥50 mIU/mL